Search Result

Results for "

Ba/F3_L858R/T790M/C797S

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (1) Ack1 (1) ADC Antibody (2) ADC Linker (1) Adrenergic Receptor (2) Akt (3) Aldose Reductase (1) Anaplastic lymphoma kinase (ALK) (4) Antibiotic (3) Apical Sodium-Dependent Bile Acid Transporter (1) Apoptosis (35) Arrestin (2) Autophagy (10) Bacterial (4) Bcl-2 Family (1) Bcr-Abl (6) Biochemical Assay Reagents (1) BMX Kinase (1) Bombesin Receptor (2) Btk (5) c-Met/HGFR (5) Calcium Channel (5) Caspase (1) CCR (2) CDK (1) Chloride Channel (1) Discoidin Domain Receptor (1) EGFR (140) Endogenous Metabolite (4) FLT3 (4) Fungal (2) G protein-coupled Bile Acid Receptor 1 (1) HBV (2) HIV (2) Isotope-Labeled Compounds (8) JAK (2) JNK (1) Ligands for E3 Ligase (4) mAChR (6) MEK (1) MicroRNA (4) mTOR (1) Nucleoside Antimetabolite/Analog (1) p38 MAPK (4) Parasite (1) Phosphatase (1) Phosphodiesterase (PDE) (1) PKC (3) PROTACs (3) Raf (2) Reactive Oxygen Species (1) RET (1) SARS-CoV (6) Small Interfering RNA (siRNA) (1) TAM Receptor (1) Thyroid Hormone Receptor (2) Transketolase (1) Trk Receptor (7)
By Research Areas:	Cancer (179) Cardiovascular Disease (5) Endocrinology (3) Infection (16) Inflammation/Immunology (6) Metabolic Disease (8) Neurological Disease (8)
Click Chemistry:	Alkynes (5)

235

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-138072

EMI1	EGFR	Cancer
EMI1 is an EGFR ex19del/T790M/C797S and EGFR L858R/T790M/C797S inhibitor. EMI1 can be used for the research of mutant EGFR-associated, drug-resistant non-small-cell lung cancer (NSCLC) .

HY-137191

CH7233163	EGFR	Cancer
CH7233163 is a noncovalent ATP-competitive inhibitor for *EGFR*-Del19/T790M/C797S. CH7233163 can overcome Osimertinib (HY-15772)-Resistant EGFR-Del19/T790M/C797S mutation. CH7233163 blocks the EGFR phosphorylation in the Del19/T790M/C797S_NIH3T3 cells. CH7233163 has antitumor activities .

HY-142519

EGFR-IN-27	EGFR	Cancer
EGFR-IN-27 is a potent EGFR inhibitor with IC₅₀s of <50 nM for EGFR Del, L858R, Del/T790M, L858R/T790M, Del/T790M/C797S, and L858R/T790M/C797S, respectively (WO2021249324A1, compound 511) .

HY-142512

EGFR-IN-24

EGFR Cancer

EGFR-IN-24, a potent EGFR inhibitor, shows inhibition against EGFR(del19/T790M/C797S) and EGFR(L858R/T790M/C797S), respectively .

EGFR-IN-24	EGFR	Cancer
EGFR-IN-24, a potent EGFR inhibitor, shows inhibition against EGFR(del19/T790M/C797S) and EGFR(L858R/T790M/C797S), respectively .

HY-157432

EGFR-IN-97	EGFR Apoptosis	Cancer
EGFR-IN-97 (compound 6q) is a EGFR inhibitor. EGFR-IN-97 shows inhibitory activity against Ba/F3-EGFR ^{L858R/T790M/C797S} and Ba/F3-EGFR ^{Del19/T790M/C797S} cells, with IC₅₀ values of 0.42 μM and 0.41 μM, respectively. EGFR-IN-97 can promote apoptosis of NCI-H1975-EGFR ^{L858R/T790M/C797S} cells at the concentration of 0.8 μM .

HY-162299

EGFR kinase inhibitor 3	EGFR	Cancer
EGFR kinase inhibitor 3 (compound 2) is a bivalent ATP-allosteric EGFR kinase inhibitor with IC₅₀s of <10 nM, 1.5 nM, 0.059 nM, 0.064 nM for WT EGFR, EGFR-activating mutations L858R, L858R/T790M and L858R/T790M/C797S, respectively. EGFR kinase inhibitor 3 is a C-linked inhibitor .

HY-163094

EGFR-IN-95	EGFR	Cancer
EGFR-IN-95 (compound 5j) is an 2,4-diaminonicotinamide derivative. EGFR-IN-95 has potent inhibitory activity against EGFR del19/T790M/C797S and L858R/T790M/C797S .

HY-161126

EGFR-IN-98	EGFR	Cancer
EGFR-IN-98 (Compound 4c) is a EGFR inhibitor. The IC₅₀ values of L858R/T790M/C797S and Del19/T790M/C797S are 0.277 μM and 0.089 μM, respectively. EGFR-IN 98 can be used in the study of tumors .

HY-150610

EGFR-IN-69	EGFR	Cancer
EGFR-IN-69 (compound 17g) is a potent EGFR inhibitor, with IC₅₀ values of 4.3, 6.6 and 25.6 nM against EGFR ^{L858R/T790M/C797S}, EGFR ^L858R/T790M, and EGFR ^{19del/T790M/C797S}, respectively. EGFR-IN-69 can be used for non-small-cell-lung-cancer (NSCLC) research .

HY-161269

EGFR-IN-101	EGFR	Cancer
EGFR-IN-101 (I-10) is a 2-phenylamino pyrimidine derivative. EGFR-IN-101 is a EGFR inhibitor. The IC₅₀ values for EGFR ^{L858R/T790M/C797S} and Ba/F3-EGFR ^{L858R/T790M/C797S} are 33.26 and 106.4 nM, respectively. EGFR-IN-101 can be used IN the study of non-small cell lung cancer (NSCLC) .

HY-155358

Os30	EGFR Apoptosis	Cancer
Os30, a potent fourth-generation EGFR inhibitor, is a potent *EGFRC797S-TK* inhibitor with IC₅₀ values of 18 nM and 113 nM for EGFRDel19/T790M/C797S TK and EGFRL858R/T790M/C797S TK, respectively. Os30 can suppress EGFR phosphorylation, arrest at G1 phase and induce the apoptosis of KC-0116 (BaF3-EGFRDel19/T790M/C797S) cells. Os30 shows potent antitumor efficacy on non-small cell lung cancer (NSCLC) with EGFmRC797S mutation .

HY-157166

EGFR kinase inhibitor 2	EGFR	Cancer
EGFR kinase inhibitor 2 (compound A-7) is a potent EGFR inhibitor targeting EGFR ^{L858R/T790M/C797S} and EGFR ^{Del19/T790M/C797S} mutants. EGFR kinase inhibitor 2 has the potential to address acquired resistance in the treatment of non-small cell lung cancer .

HY-130616

EGFR-IN-11	EGFR Apoptosis	Cancer
EGFR-IN-11 is a fourth-generation EGFR-tyrosine kinase inhibitor (EGFR-TKI) with an IC₅₀ of 18 nM for triple mutant EGFR ^{L858R/T790M/C797S}. EGFR-IN-11 significantly suppresses the EGFR phosphorylation, induce the apoptosis, and arrest cell cycle at G0/G1 .

HY-119944

JND3229	EGFR	Cancer
JND3229 is a reversible EGFR ^C797S inhibitor with IC₅₀ values of 5.8, 6.8 and 30.5 nM for EGFR ^{L858R/T790M/C797S}, EGFR ^WT and EGFR ^L858R/T790M, respectively. JND3229 has good anti-proliferative activity and can effectively inhibit tumour growth in vivo. JND3229 can be used in cancer research, especially in non-small cell carcinoma .

HY-155005

EGFR mutant-IN-2	EGFR	Cancer
EGFR mutant-IN-2 (Compound D51) is an EGFR mutant inhibitor. EGFR mutant-IN-2 inhibits the EGFR ^{L858R/T790M/C797S} mutant with an IC₅₀ value of 14 nM. EGFR mutant-IN-2 inhibits the EGFR ^{del19/T790M/C797S} mutant with an IC₅₀ value of 62 nM. EGFR mutant-IN-2 has favorable PK parameters, safety properties, in vivo stability, and antitumor activity .

HY-111415

EGFR-IN-5

EGFR Cancer

EGFR-IN-5 is a EGFR inhibitor with IC₅₀s of 10.4, 1.1, 34, 7.2 nM for EGFR, EGFR ^L858R, EGFR ^L858R/T790M, and EGFR ^{L858R/T790M/C797S}, respectively.

EGFR-IN-5	EGFR	Cancer
EGFR-IN-5 is a EGFR inhibitor with IC₅₀s of 10.4, 1.1, 34, 7.2 nM for EGFR, EGFR ^L858R, EGFR ^L858R/T790M, and EGFR ^{L858R/T790M/C797S}, respectively.

HY-130608

Mutated EGFR-IN-3	EGFR	Cancer
Mutated EGFR-IN-3 (compound 3) is a potent, ATP-competitive and highly selective allosteric dibenzodiazepinone inhibitor of the *EGFR(L858R/T790M)* and *EGFR(L858R/T790M/C797S)* mutants with IC₅₀ values of 12 nM and 13 nM, respectively .

HY-156457

EGFR-IN-90	EGFR	Cancer
EGFR-IN-90 (compound 34) is an orally active EGFR inhibitor. EGFR-IN-90 shows inhibitory activity against EGFRL858R/T790M/C797S with an IC₅₀ of 5.1 nM and inhibits the proliferation of the H1975-TM cell line harboring EGFRL858R/T790M/C797S with an IC₅₀ of 0.05 μM. EGFR-IN-90 and inhibits tumor growth in the H1975-TM xenograft tumor model .

HY-152019

*EGFR/C797S-IN-1*	EGFR	Cancer
EGFR/C797S-IN-1 is a potent *EGFR-C797S* inhibitor with an IC₅₀ value of 0.128 µM. EGFR/C797S-IN-1 shows anti-proliferative activity and anti-tumor activity. EGFR/C797S-IN-1 inhibits the expression of p-EGFR in a dose-dependent manner .

HY-139884

EGFR-IN-18

EGFR Cancer

EGFR-IN-18 potently inhibits enzymatic activity in L858R/T790M/C797S mutant EGFR (4.9 nM), with a significantly lower activity for wild-type EGFR (47 nM).

EGFR-IN-18	EGFR	Cancer
EGFR-IN-18 potently inhibits enzymatic activity in L858R/T790M/C797S mutant EGFR (4.9 nM), with a significantly lower activity for wild-type EGFR (47 nM).

HY-143445

EGFR-IN-48	EGFR	Cancer
EGFR-IN-48 is a potent and orally active EGFR inhibitor with IC₅₀s of 0.193 nM, 0.251 nM, 10.4 nM for EGFR ^d19/TM/CS, EGFR ^LR/TM/CS, EGFR ^WT, respectively. EGFR-IN-48 inhibits the proliferation of BaF3 ^{EGFR del19/T790M/C797S} and PC-9 ^{EGFR del19/T790M/C797S} cells with IC₅₀s of 1.526, 66.7 nM, respectively .

HY-149401

EGFR-IN-82	EGFR	Cancer
EGFR-IN-82 (Cmpound 8a) is a potent and orally active EGFR inhibitor with IC₅₀ values of 0.09 and 0.06 nM for EGFR ^{L858R/T790M/C797S} and EGFR ^{Del19/T790M/C797S}, respectively. EGFR-IN-82 has no significant effect on EGFR ^WT. EGFR-IN-82 has anti-proliferative activity and inhibits tumor formation in nude mice. EGFR-IN-82 can be used in non-small cell lung cancer research .

HY-161319

EGFR-IN-104	EGFR	Cancer
EGFR-IN-104 (Compound A23) is an effective inhibitor of EGFR, with IC₅₀ values of 0.33 μM and 0.133 μM against EGFR ^L858R/T790M and EGFR ^{Del19/T790M/C797S}, respectively. EGFR-IN-104 exhibits anticancer activity both in vitro and in vivo .

HY-142517

EGFR-IN-25

EGFR Cancer

EGFR-IN-25 is a potent EGFR inhibitor with IC₅₀s of 9 nM and 60 nM for BaF3 cells (EGFR DEL19/T790M/C797S) and A431 cells (WT), respectively .

EGFR-IN-25	EGFR	Cancer
EGFR-IN-25 is a potent EGFR inhibitor with IC₅₀s of 9 nM and 60 nM for BaF3 cells (EGFR DEL19/T790M/C797S) and A431 cells (WT), respectively .

HY-157994

*EGFR WT/T790M-IN-2*	EGFR Apoptosis	Cancer
EGFR WT/T790M-IN-2 (Compound 7c) is a EGFR T790M/WT inhibitor with IC₅₀ values of 0.08 and 0.13 μM, respectively. EGFR WT/T790M-IN-2 induces apoptosis by blocking the G0-G1 phase (apoptosis). EGFR WT/T790M-IN-2 has antitumor activity .

HY-142679

EGFR-IN-22	EGFR	Cancer
EGFR-IN-22 is a potent EGFR inhibitor with IC₅₀s of 4.91 nM and 0.54 nM for wild type EGFR and EGFR ^{L858R/T790M/C797S}, respectively (CN112538072A, compound 243) .

HY-142680

EGFR-IN-23

EGFR Cancer

EGFR-IN-23 is a potent EGFR TKI (tyrosine kinase inhibitor) with an IC₅₀ of 8.05 nM for BaF3/EGFR-DEL19/T790M/C797S cell (WO2021244502A1, compound 8) .

EGFR-IN-23	EGFR	Cancer
EGFR-IN-23 is a potent EGFR TKI (tyrosine kinase inhibitor) with an IC₅₀ of 8.05 nM for BaF3/EGFR-DEL19/T790M/C797S cell (WO2021244502A1, compound 8) .

HY-161275

BI-4732	EGFR	Cancer
BI-4732 a potent inhibitor EGFR-activating (E19del and L858R) and T790M mutations, with high blood-brian barrier penetration, targeting a broad range of EGFR mutations, including C797S. BI-4732 has anti-tumor activity .

HY-163371

*EGFR WT/T790M-IN-1*	EGFR Apoptosis	Cancer
EGFR WT/T790M-IN-1 (Compound 16h) is a dual EGFR WT and EGFR T790 inhibitor. EGFR WT/T790M-IN-1 can arrest the cell cycle in G2/M phase and induce apoptosis. EGFR WT/T790M-IN-1 has anti-cancer activity .

HY-156284

EGFR-IN-89	EGFR	Cancer
EGFR-IN-89 (compound 13k) is a potent, fourth-generation EGFR mutation inhibitor with an IC₅₀ of 10.1 nM against Del19/T790M/C797S mutations. EGFR-IN-89 shows higher selectivity over wild type .

HY-144680

BLU-945 ZL-2313	EGFR	Cancer
BLU-945 is a potent, highly selective, reversible and orally active epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKIs). BLU-945 can effectively inhibit EGFR with L858R and/or exon 19 deletion mutation, T790M mutation and C797S mutation. BLU-945 can be used for the research of lung cancer including non-small cell lung cancer (NSCLC) .

HY-135805

JBJ-04-125-02	EGFR	Cancer
JBJ-04-125-02 is a potent, mutant-selective, allosteric and orally active EGFR inhibitor with an IC₅₀ of 0.26 nM for EGFR ^L858R/T790M. JBJ-04-125-02 can inhibit cancer cell proliferation and EGFR ^{L858R/T790M/C797S} signaling. JBJ-04-125-02 has anti-tumor activities .

HY-125841

EGFR mutant-IN-1	EGFR	Cancer
EGFR mutant-IN-1, a 5-methylpyrimidopyridone derivative, is a potent and selective EGFR ^{L858R/T790M/C797S} mutant inhibitor with an IC₅₀ of 27.5 nM, while being a significantly less potent for EGFR ^WT (IC₅₀ >1.0 μM) .

HY-144044

EGFR-IN-30	EGFR	Cancer
EGFR-IN-30 is a potent EGFR inhibitor with IC₅₀s of 1-10 nM, <1 nM for EGFR (WT), EGFR (L858R/T790M/C797S), respectively. EGFR-IN-30 has potential for cell proliferative diseases, such as cancer research .

HY-157398

*EGFR T790M/L858R-IN-3*	EGFR	Cancer
EGFR T790M/L858R-IN-3 (compound B1) is a EGFR ^L858R/T790M inhibitor with IC₅₀ value of 13?nM. EGFR T790M/L858R-IN-3 shows anti-tumour activity in H1975 cells with an IC₅₀ value of 0.087 μΜ. EGFR T790M/L858R-IN-3 inhibits cell migration in A549 cells and induces apoptosis in H1975 cells .

HY-143337

EGFR-IN-47	Apoptosis EGFR	Cancer
EGFR-IN-47 is a potent and orally active EGFR ^{L858R/T790M/C797S} inhibitor with an IC₅₀ of 0.01 µM. EGFR-IN-47 induces cell cycle attest and cell apoptosis. EGFR-IN-47 has the potential for the research of NSCLC .

HY-162062

*EGFR WT/T790M/L858R-IN-1*	EGFR	Cancer
EGFR WT/T790M/L858R-IN-1 (compound 10d) is a potent EGFR inhibitor, with IC₅₀s of 0.097, 0.280, and 0.051?μM for EGFR ^WT, EGFR ^T790M, and EGFR ^L858R, respectively. EGFR WT/T790M/L858R-IN-1 can be used for the research of cancer .

HY-128862

EGFR-IN-7	EGFR	Cancer
EGFR-IN-7 is a potent, selective and orally active EGFR kinase inhibitor. EGFR-IN-7 has inhibitory effect for for EGFR (WT) and EGFR (mutant C797S/T790M/L858R) with IC₅₀ values of 7.92 nM and 0.218 nM, respectively. EGFR-IN-7 can be used for the research of various cancers .

HY-143246

EGFR kinase inhibitor 1	EGFR Apoptosis	Cancer
EGFR kinase inhibitor 1 is a potent EGFR inhibitor with IC₅₀s of 37, 1.7, >300 nM for WT, l885R/T790M, L858R/T790M/C797S, respectively. EGFR kinase inhibitor 1 induces apoptosis and cell cycle arrest at G0/G1-phase. EGFR kinase inhibitor 1 inhibits the cell motility. EGFR kinase inhibitor 1 shows antiproliferative and anti-tumor activity .

HY-129550

BI-4020	EGFR	Cancer
BI-4020 is a fourth-generation, orally active, and non-covalent EGFR tyrosine kinase inhibitor. BI-4020 inhibits not only the triple mutant EGFR del19 T790M C797S variant (IC₅₀=0.2 nM in BaF3 cell lines) but also the double mutant EGFR del19 T790M and primary mutant EGFR del19 (IC₅₀=1 nM). BI-4020 also shows activity against EGFR wt (IC₅₀=190 nM). BI-4020 shows high kinome selectivity and good DMPK properties .

HY-147183

JBJ-09-063	EGFR	Cancer
JBJ-09-063 is a mutant-selective allosteric EGFR inhibitor with IC₅₀s of 0.147 nM, 0.063 nM, 0.083 nM and 0.396 nM for EGFR L858R, EGFR L858R/T790M, EGFR L858R/T790M/C797S and EGFRLT/L747S. JBJ-09-063 effectively reduces EGFR, Akt and ERK1/2 phosphorylation. JBJ-09-063 is effective across EGFR tyrosine kinase inhibitor (TKI)-sensitive and resistant models. JBJ-09-063 can be used for researching EGFR-mutant lung cancer .

HY-147183A

JBJ-09-063 TFA	EGFR	Cancer
JBJ-09-063 TFA is a mutant-selective allosteric EGFR inhibitor with IC₅₀s of 0.147 nM, 0.063 nM, 0.083 nM and 0.396 nM for EGFR L858R, EGFR L858R/T790M, EGFR L858R/T790M/C797S and EGFRLT/L747S. JBJ-09-063 TFA effectively reduces EGFR, Akt and ERK1/2 phosphorylation. JBJ-09-063 TFA is effective across EGFR tyrosine kinase inhibitor (TKI)-sensitive and resistant models. JBJ-09-063 TFA can be used for researching EGFR-mutant lung cancer .

HY-147183B

JBJ-09-063 hydrochloride	EGFR	Cancer
JBJ-09-063 hydrochloride is a mutant-selective allosteric EGFR inhibitor with IC₅₀s of 0.147 nM, 0.063 nM, 0.083 nM and 0.396 nM for EGFR L858R, EGFR L858R/T790M, EGFR L858R/T790M/C797S and EGFRLT/L747S. JBJ-09-063 hydrochloride effectively reduces EGFR, Akt and ERK1/2 phosphorylation. JBJ-09-063 hydrochloride is effective across EGFR tyrosine kinase inhibitor (TKI)-sensitive and resistant models. JBJ-09-063 hydrochloride can be used for researching EGFR-mutant lung cancer .

HY-112823B

Almonertinib hydrochloride 3 Publications Verification HS-10296 hydrochloride	EGFR	Cancer
Almonertinib (HS-10296) hydrochloride is an orally available, irreversible, third-generation EGFR tyrosine kinase inhibitor with high selectivity for EGFR-sensitizing and T790M resistance mutations. Almonertinib hydrochloride shows great inhibitory activity against T790M, T790M/L858R and T790M/Del19 (IC₅₀: 0.37, 0.29 and 0.21 nM, respectively), and is less effective against wild type (3.39 nM). Almonertinib hydrochloride is used for the research of the non-small cell lung cancer .

HY-112823

Almonertinib 3 Publications Verification HS-10296	EGFR	Cancer
Almonertinib (HS-10296) is an orally available, irreversible, third-generation EGFR tyrosine kinase inhibitor with high selectivity for EGFR-sensitizing and T790M resistance mutations. Almonertinib shows great inhibitory activity against T790M, T790M/L858R and T790M/Del19 (IC₅₀: 0.37, 0.29 and 0.21 nM, respectively), and is less effective against wild type (3.39 nM). Almonertinib is used for the research of the non-small cell lung cancer .

HY-112823A

Almonertinib mesylate 3 Publications Verification HS-10296 mesylate	EGFR	Cancer
Almonertinib (HS-10296) mesylate is an orally available, irreversible, third-generation EGFR tyrosine kinase inhibitor with high selectivity for EGFR-sensitizing and T790M resistance mutations. Almonertinib mesylate shows great inhibitory activity against T790M, T790M/L858R and T790M/Del19 (IC₅₀: 0.37, 0.29 and 0.21 nM, respectively), and is less effective against wild type (3.39 nM). Almonertinib mesylate is used for the research of the non-small cell lung cancer .

HY-162254

EGFR/ACK1-IN-1	EGFR Ack1	Cancer
EGFR T790M/L858R/ACK1-IN-1 is a dual inhibitor of EGFR T790M/L858R and ACK1. IC₅₀ values are 23 and 263 nM, respectively. EGFR T790M/L858R/ACK1-IN-1 can inhibit cell proliferation and has antitumor activity .

HY-15729

Rociletinib 10+ Cited Publications CO-1686; AVL-301; CNX-419	EGFR	Cancer
Rociletinib (CO-1686) is an orally delivered kinase inhibitor that specifically targets the mutant forms of EGFR including T790M, and the K_i values for EGFRL858R/T790M and EGFRWT are 21.5 nM and 303.3 nM, respectively.

HY-12026

WZ4002 5+ Cited Publications	EGFR	Cancer
WZ4002 is a mutant selective EGFR inhibitor with IC₅₀s of 2, 8, 3 and 2 nM for EGFR ^L858R, EGFR ^L858R/T790M, EGFR ^E746_A750 and EGFR ^{E746_A750/T790M}, respectively.

HY-15729A

Rociletinib hydrobromide 10+ Cited Publications CO-1686 hydrobromide; AVL-301 hydrobromide; CNX-419 hydrobromide	EGFR	Cancer
Rociletinib hydrobromide (CO-1686 hydrobromide) is an orally delivered kinase inhibitor that specifically targets the mutant forms of EGFR including T790M, and the K_i values for EGFRL858R/T790M and EGFRWT are 21.5 nM and 303.3 nM, respectively.

Cat. No.	Product Name	Target	Research Area

HY-P1423A

BA 1 TFA	Bombesin Receptor	Metabolic Disease Cancer
BA 1 TFA is a potent agonist for the bombesin (BB) family of receptors. BA1 binds with high affinity to Bombesin receptor subtype-3 (BRS3), gastrin releasing peptide receptor (GRPR), neuromedin B receptor (NMBR) with IC₅₀s of 6, 0.4, 2.5 nM .

HY-108742

Abaloparatide 1 Publications Verification Ba 058; BIM 44058	Thyroid Hormone Receptor Arrestin	Metabolic Disease
Abaloparatide (BA 058) is a parathyroid hormone receptor 1 (PTHR1) analog. Abaloparatide also is a selective PTHR1 activator. Abaloparatide enhances Gs/cAMP signaling and β-arrestin recruitment. Abaloparatide enhances bone formation and cortical structure in mice. Abaloparatide has the potential for the research of osteoporosis .

HY-108742A

Abaloparatide TFA 1 Publications Verification Ba 058 TFA; BIM 44058 TFA	Thyroid Hormone Receptor Arrestin	Metabolic Disease Endocrinology
Abaloparatide TFA (BA 058 TFA) is a parathyroid hormone receptor 1 (PTHR1) analogue. Abaloparatide TFA also is a selective PTHR1 activator. Abaloparatide TFA enhances Gs/cAMP signaling and β-arrestin recruitment. Abaloparatide TFA enhances bone formation and cortical structure in mice. Abaloparatide TFA has the potential for the research of osteoporosis .

HY-P1423

BA 1	Bombesin Receptor	Metabolic Disease Cancer
BA 1 is a potent agonist for the bombesin (BB) family of receptors. BA 1 binds with high affinity to Bombesin receptor subtype-3 (BRS3), gastrin releasing peptide receptor (GRPR), neuromedin B receptor (NMBR) with IC₅₀s of 6, 0.4, 2.5 nM .

HY-P10013

Codactide

Ba-41795
Peptides Endocrinology

Codactide is a synthetic octadecapeptide, with corticotropin-like action .

HY-P3973

Thrombostatin cont-1	Peptides	Others
Thrombostatin cont-1 is an analogue of thrombostatin, which is a a bradykinin metabolite. Thrombostatin could decrease platelet activation in the canine carotid artery model of balloon angioplasty (BA) injury .

HY-P5820

ω-Conotoxin Bu8	Calcium Channel	Neurological Disease
ω-Conotoxin Bu8 is a ω-conotoxin, which consists of 25 amino acid residues and three disulfide bridges. ω-Conotoxin Bu8 selectively and potently inhibits depolarization-activated Ba₂₊ currents mediated by rat CaV2.2 expressed in HEK293T cells (IC₅₀= 89 nM) .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0309

Soyasaponin Ba	Triterpenes Structural Classification Classification of Application Fields Leguminosae Glycine max (L.) merr Terpenoids Source classification Metabolic Disease Plants Disease Research Fields	Aldose Reductase
Soyasaponin Ba is a soyasaponin isolated from Phaseolus vulgaris, acts as an aldose reductase inhibitors (ARI) .

HY-118384

Sangivamycin 2 Publications Verification NSC 65346; Ba-90912	Structural Classification Natural Products Microorganisms Classification of Application Fields Source classification Disease Research Fields Cancer	PKC Nucleoside Antimetabolite/Analog
Sangivamycin (NSC 65346), a nucleoside analog, is a potent inhibitor of protein kinase C (PKC) with an K_i of 10 μM. Sangivamycin has potent antiproliferative activity against a variety of human cancers .

HY-13434

Ionomycin Maximum Cited Publications 48 Publications Verification SQ23377	Infection Structural Classification Microorganisms Classification of Application Fields Antibiotics Source classification Disease Research Anticancer Disease Research Fields Other Antibiotics	Calcium Channel PKC Bacterial Apoptosis Antibiotic
Ionomycin (SQ23377) is a potent, selective calcium ionophore and an antibiotic produced by Streptomyces conglobatus. Ionomycin (SQ23377) is highly specific for divalent cations (Ca>Mg>Sr=Ba). Ionomycin (SQ23377) promotes apoptosis. Ionomycin also induces the activation of protein kinase C (PKC) .

HY-N10443

Mammea A/BA	other families Source classification Coumarins Phenylpropanoids Plants Calophyllum brasiliense auct. non Camb.	Parasite Apoptosis Autophagy Reactive Oxygen Species
Mammea A/BA has potent activity against Trypanosoma cruzi (T. cruzi). Mammea A/BA induces mitochondrial dysfunction, reactive oxygen species (ROS) production and DNA fragmentation, and increases number of acidic vacuoles. Mammea A/BA can induce apoptosis, autophagy and necrosis. Mammea A/BA can be used for researching chagas disease .

HY-N4080

Cyclobuxine D	other families Classification of Application Fields Source classification Plants Disease Research Fields Inflammation/Immunology Steroids	mAChR
Cyclobuxine D is a steroidal alkaloid extracted from Buxus microphylla. Cyclobuxine D has a significant bradycardic effect in the rat heart and an inhibitory action on acetylcholine and Ba ⁺⁺−induced contraction of the longitudinal muscle isolated from the rabbit jejunum .

HY-13434A

Ionomycin calcium Maximum Cited Publications 48 Publications Verification SQ23377 calcium	Infection Structural Classification Microorganisms Classification of Application Fields Antibiotics Source classification Disease Research Anticancer Disease Research Fields Other Antibiotics	Calcium Channel PKC Bacterial Apoptosis Antibiotic
Ionomycin calcium (SQ23377 calcium) is a potent, selective calcium ionophore and an antibiotic produced by Streptomyces conglobatus. Ionomycin calcium (SQ23377 calcium) is highly specific for divalent cations (Ca>Mg>Sr=Ba). Ionomycin (SQ23377) promotes apoptosis. Ionomycin calcium (SQ23377 calcium) also induces the activation of protein kinase C (PKC) .

Species:	Human (12) Rat (1) Mouse (3) Cynomolgus (1)
Tag:	His (16) SUMO (2) Avi (3) GST (2) Flag (1)
Source:	HEK293 (10) Sf9 insect cells (1) E. coli (6)

Cat. No.	Compare	Product Name	Species	Source

HY-P73934

	Haptoglobin Protein, Rat (HEK293, His) Haptoglobin; Zonulin; HP; Ba1-647	Rat	HEK293
	Haptoglobin Proteinas, a positive regulator of collagen fibrillogenesis, likely plays a crucial role in extracellular matrix organization and remodeling. Its involvement extends to positively regulating MAP-kinase activity, contributing to increased adipocyte proliferation and diminished differentiation. Haptoglobin may also serve as a positive regulator of NF-kappa-B activity in macrophages, enhancing inflammatory responsiveness. Additionally, it exhibits transcriptional repressor activity, suggesting its role in gene expression modulation. Haptoglobin Protein, Rat (HEK293, His) is the recombinant rat-derived Haptoglobin protein, expressed by HEK293, with C-His labeled tag. The total length of Haptoglobin Protein, Rat (HEK293, His) is 347 a.a., with molecular weight of ~38.1 kDa.

HY-P77951

	CD42b/GP1BA Protein, Human (515a.a, HEK293, His) GP-Ib alpha; GPIb-alpha; GPIBa; GP1Ba; BDPLT1; BDPLT3; BSS; CD42B; CD42b-alpha; DBPLT3; GP1B; VWDP; BP1Ba; MGC34595	Human	HEK293
	CD42b/GP1BA protein is an important platelet membrane protein that interacts with the A1 domain of von Willebrand factor and contributes to the formation of subendothelial platelet plugs. Its GP1BA subunit forms a disulfide-linked complex with two GP1BB subunits, collectively called GP-Ib. CD42b/GP1BA Protein, Human (515a.a, HEK293, His) is the recombinant human-derived CD42b/GP1BA protein, expressed by HEK293 , with C-His labeled tag. The total length of CD42b/GP1BA Protein, Human (515a.a, HEK293, His) is 515 a.a., with molecular weight of 100-130 kDa.

HY-P76804

	CD42b/GP1BA Protein, Human (519a.a, HEK293, His) Platelet glycoprotein Ib alpha; GP1Ba	Human	HEK293
	CD42b/GP1BA protein is an important platelet membrane protein that interacts with the A1 domain of von Willebrand factor and contributes to the formation of subendothelial platelet plugs. Its GP1BA subunit forms a disulfide-linked complex with two GP1BB subunits, collectively called GP-Ib. CD42b/GP1BA Protein, Human (519a.a, HEK293, His) is the recombinant human-derived CD42b/GP1BA protein, expressed by HEK293 , with C-His labeled tag. The total length of CD42b/GP1BA Protein, Human (519a.a, HEK293, His) is 503 a.a., with molecular weight of ~93 kDa.

HY-P7752

	Cathepsin H Protein, Mouse (HEK293, His) rMuCathepsin H, His; Pro-cathepsin H; CTSH; ACC-4; ACC-5; aleurain; cathepsin B3; cathepsin Ba; cathepsin H; CPSB;	Mouse	HEK293
	Cathepsin H Protein, Mouse (HEK293, His) is an approximately 36-40 kDa cathepsin H protein with a His-flag. Cathepsin H is a lysosomal cysteine protease of the papain family.

HY-P72137

	CFB Protein, Mouse (His) 1 Publications Verification Cfb; Bf; H2-BfComplement factor B; EC 3.4.21.47; C3/C5 convertase; Complement factor B Ba fragment; Complement factor B Bb fragment	Mouse	E. coli
	CFB is an important component of the alternative pathway of the complement system and is cleaved by factor D, producing two fragments: Ba and Bb. The Bb fragment is characterized as a serine protease and subsequently forms a complex with complement factor 3b, ultimately producing a C3 or C5 convertase. CFB Protein, Mouse (His) is the recombinant mouse-derived CFB protein, expressed by E. coli , with N-6*His labeled tag. The total length of CFB Protein, Mouse (His) is 739 a.a., with molecular weight of ~87 kDa.

HY-P77749

	MFG-E8 Protein, Mouse (HEK293, His) Lactadherin; MFGM; MFG-E8; SED1; MP47; Ba46; EDIL1; HsT19888; Medin; MFG1; OAcGD3S; SPAG10	Mouse	HEK293
	The MFG-E8 protein plays a critical role in promoting the phagocytic clearance of apoptotic cells in various tissues. As a specific ligand, it interacts with alpha-v/beta-3 and alpha-v/beta-5 receptors and also binds independently to phosphatidylserine-rich cell surfaces. MFG-E8 Protein, Mouse (HEK293, His) is the recombinant mouse-derived MFG-E8 protein, expressed by HEK293 , with N-His labeled tag. The total length of MFG-E8 Protein, Mouse (HEK293, His) is 441 a.a., with molecular weight of 60-70 kDa.

HY-P70170

	Fetuin A/AHSG Protein, Human (HEK293, His) rHuAlpha-2-HS-glycoprotein/AHSG, His; Alpha-2-HS-Glycoprotein; Alpha-2-Z-Globulin; Ba-Alpha-2-Glycoprotein; Fetuin-A; AHSG; FETUA	Human	HEK293
	Fetuin A (or AHSG protein) plays multiple roles in cellular processes, promotes endocytosis and displays opsonic properties. It regulates the mineral phase of bone, affects bone homeostasis, and has significant affinity for calcium and barium ions. Fetuin A/AHSG Protein, Human (HEK293, His) is the recombinant human-derived Fetuin A/AHSG protein, expressed by HEK293 , with C-6*His labeled tag. The total length of Fetuin A/AHSG Protein, Human (HEK293, His) is 349 a.a., with molecular weight of ~60.0 kDa.

HY-P71580

	GFRAL Protein, Human (His-SUMO) Ba360D14.1; C6orf144; GDNF family receptor alpha-like; Gfral; GFRAL_HUMAN; GRAL; IVFI9356; UNQ9356; UNQ9356/PRO34128	Human	E. coli
	The GFRAL protein is a brainstem-restricted receptor for GDF15 that regulates food intake, energy expenditure, and body weight in response to metabolic and toxin-induced stress. GFRAL binds to its ligand GDF15, interacts with RET, and activates the MAPK and AKT signaling pathways. GFRAL Protein, Human (His-SUMO) is the recombinant human-derived GFRAL protein, expressed by E. coli , with N-His, N-SUMO labeled tag. The total length of GFRAL Protein, Human (His-SUMO) is 333 a.a., with molecular weight of ~53.8 kDa.

HY-P78521

	SIRP gamma Protein, Human (HEK293, His-Avi) CD172g; FLJ42230; SIRP beta 2; SIRP gamma; SIRP-B2; SIRPG; Cripto-1; Ba77C3.1; SIRP β 2	Human	HEK293
	SIRP gamma Protein, a probable immunoglobulin-like cell surface receptor, mediates cell-cell adhesion by binding with CD47. This interaction enhances antigen-specific T-cell proliferation and provides costimulatory signals for T-cell activation, highlighting SIRP gamma's role in modulating immune responses. The intricate interactions with CD47 underscore SIRP gamma's significance as a cell surface receptor, crucial in cellular adhesion and regulating T-cell activation pathways. SIRP gamma Protein, Human (HEK293, His-Avi) is the recombinant human-derived SIRP gamma protein, expressed by HEK293, with C-His, C-Avi labeled tag. The total length of SIRP gamma Protein, Human (HEK293, His-Avi) is 332 a.a., with molecular weight of 47-49 kDa.

HY-P78210

	SIRP gamma Protein, Human (Biotinylated, HEK293, His-Avi) CD172g; FLJ42230; SIRP beta 2; SIRP gamma; SIRP-B2; SIRPG; Cripto-1; Ba77C3.1; SIRP β 2	Human	HEK293
	SIRP γ protein is a possible immunoglobulin-like cell surface receptor that mediates cell-cell adhesion by binding to CD47. This interaction enhances antigen-specific T cell proliferation and provides costimulatory signals for T cell activation, highlighting the role of SIRP gamma in regulating immune responses. SIRP gamma Protein, Human (Biotinylated, HEK293, His-Avi) is the recombinant human-derived SIRP gamma protein, expressed by HEK293 , with C-His, C-Avi labeled tag. The total length of SIRP gamma Protein, Human (Biotinylated, HEK293, His-Avi) is 332 a.a., with molecular weight of 48-53 kDa.

HY-P72190

	FANCC Protein, Human (His-SUMO) Ba80I15.1; FA3; FAC; FACC; FANCC; FANCC_HUMAN; Fanconi anemia complementation group C; Fanconi anemia complementation group C protein; Fanconi anemia group C protein; Fanconi pancytopenia type 3; FLJ14675; Protein FACC	Human	E. coli
	FANCC Protein repairs and maintains DNA, aids in STAT1 activation, and forms a multisubunit FA complex. It interacts with ZBTB32, STAT1, CDK1, and EIF2AK2. The FA complex excludes FA patients and may include HSP70, while interaction with EIF2AK2 leads to increased activation and cell death. FANCC Protein, Human (His-SUMO) is the recombinant human-derived FANCC protein, expressed by E. coli , with N-6*His, N-SUMO labeled tag. The total length of FANCC Protein, Human (His-SUMO) is 558 a.a., with molecular weight of ~79.4 kDa.

HY-P78505

	PD-L2 Protein, Human (HEK293, His-Avi) PDL2; PD-L2; Butyrophilin B7-DC; CD273, PDCD1 ligand 2; PDCD1L2; PDCD1LG2; B7DC; Ba574F11.2; Btdc	Human	HEK293
	PD-L2 Protein, operating independently of PDCD1, plays a vital role in T-cell proliferation and IFNG production. Its interaction with PDCD1 inhibits proliferation and cytokine production. The interplay between PD-L2 and PDCD1 regulates immune responses, influencing T-cell activation and function. This molecular interaction adds complexity to mechanisms governing T-cell behavior, highlighting PD-L2's versatile role in immune regulation. PD-L2 Protein, Human (HEK293, His-Avi) is the recombinant human-derived PD-L2 protein, expressed by HEK293 , with C-Avi, C-His labeled tag. The total length of PD-L2 Protein, Human (HEK293, His-Avi) is 201 a.a., with molecular weight of 40-52 kDa.

HY-P700894

PD-L2 Protein, Cynomolgus (HEK293, C-His)

PDL2; PD-L2; Butyrophilin B7-DC; CD273, PDCD1 ligand 2; PDCD1L2; PDCD1LG2; B7DC; Ba574F11.2; Btdc
Cynomolgus HEK293

HY-P71684

	BCAP31 Protein, Human (GST) 6C6 AG; 6C6 AG tumor associated antigen; B-cell receptor-associated protein 31; Ba31; CDM; CDM protein; DXS1357E; MS950; p28; p28 Bap31; Protein CDM; RP23-329M9.5	Human	E. coli
	The BCAP31 protein acts as a chaperone and is one of the most abundant endoplasmic reticulum (ER) proteins. The BCAP31 protein also serves as a cargo receptor for transmembrane protein export. BCAP31 stimulates the translocation of NDUFS4 and NDUFB11 to mitochondria, interacts with BCL2, and may be involved in caspase-8-mediated apoptosis. BCAP31 Protein, Human (GST) is the recombinant human-derived BCAP31 protein, expressed by E. coli , with N-GST labeled tag. The total length of BCAP31 Protein, Human (GST) is 242 a.a., with molecular weight of ~54.5 kDa.

HY-P72209

	GOLM1 Protein, Human (His) Ba379P1.3; C9orf155; Chromosome 9 open reading frame 155; Golgi membrane protein 1; Golgi membrane protein GP73; Golgi phosphoprotein 2; Golgi protein 73 kD ; Golgi protein 73kD ; GOLM 1; GOLM1; GOLM1_HUMAN; GOLPH 2; GOLPH2; GP 73; GP73; PSEC0257	Human	E. coli
	GOLM1 Protein, amid partial comprehension, acts as a cellular response protein to viral infections, with an intricate role yet to be fully understood. Interactions with DYM suggest potential links to cellular dynamics or host-virus interactions. Further investigation is crucial to delineate GOLM1's specific contributions and implications in cellular defense mechanisms against viral infections. GOLM1 Protein, Human (His) is the recombinant human-derived GOLM1 protein, expressed by E. coli , with N-6*His labeled tag. The total length of GOLM1 Protein, Human (His) is 366 a.a., with molecular weight of ~45.6 kDa.

HY-P72209A

	GOLM1 Protein, Human (His, Solution) Ba379P1.3; C9orf155; Chromosome 9 open reading frame 155; Golgi membrane protein 1; Golgi membrane protein GP73; Golgi phosphoprotein 2; Golgi protein 73 kD ; Golgi protein 73kD ; GOLM 1; GOLM1; GOLM1_HUMAN; GOLPH 2; GOLPH2; GP 73; GP73; PSEC0257	Human	E. coli
	GOLM1 Protein, amid partial comprehension, acts as a cellular response protein to viral infections, with an intricate role yet to be fully understood. Interactions with DYM suggest potential links to cellular dynamics or host-virus interactions. Further investigation is crucial to delineate GOLM1's specific contributions and implications in cellular defense mechanisms against viral infections. GOLM1 Protein, Human (His, Solution) is the recombinant human-derived GOLM1 protein, expressed by E. coli , with N-6*His labeled tag. The total length of GOLM1 Protein, Human (His, Solution) is 366 a.a., with molecular weight of ~60 kDa.

HY-P702699

	CDK19-CCNC-MED12 Protein, Human (sf9, GST, Flag, His) CDC2L6; CDK19; cyclin dependent kinase 19; CDK11; CDC2L6; Ba346C16.3; cyclin-dependent kinase 19; CDC2-related protein kinase 6; CDK8-like cyclin-dependent kinase; cell division cycle 2-like 6 (CDK8-like); cell division cycle 2-like protein kinase 6; cell division protein kinase 19; cyclin dependent kinase 19 variant 2; cyclin-dependent kinase (CDC2-like) 11; cyclin-dependent kinase 11; death-preventing kinase; EC 2.7.11.22	Human	Sf9 insect cells

Cat. No.	Product Name	Chemical Structure

HY-15772S

Osimertinib-d6
Osimertinib-d₆ is a deuterium labeled osimertinib. Osimertinib is a covalent, orally active, irreversible, and mutant-selective EGFR inhibitor with an apparent IC50 of 12 nM against L858R and 1 nM against L858R/T790M. Osimertinib overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer[1].

HY-15772S1

Osimertinib-13C,d3
Osimertinib- ¹³C,d₃ is the deuterium and ¹³C labeled Osimertinib. Osimertinib (AZD9291) is a covalent, orally active, irreversible, and mutant-selective EGFR inhibitor with an apparent IC50 of 12 nM against L858R and 1 nM against L858R/T790M, respectively.

HY-15164AS

Icotinib-d4

Icotinib-d₄ is the deuterium-labeled Icotinib (HY-15164A). Icotinib-d₄ (BPI-2009) is a potent and specific EGFR inhibitor with an IC₅₀ of 5 nM; also inhibits mutant EGFR ^L858R, EGFR ^L858R/T790M, EGFR ^T790M and EGFR ^L861Q. Icotinib-d₄ is a click chemistry reagent, itcontains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-10261S1

Afatinib-d4
Afatinib-d₄ is the deuterium labeled Afatinib. Afatinib (BIBW 2992) is an irreversible EGFR family inhibitor with IC50s of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFRwt, EGFRL858R, EGFRL858R/T790M and HER2, respectively.

HY-10261AS

Afatinib-d6 dimaleate
Afatinib-d₆ (dimaleate) is the deuterium labeled Afatinib dimaleate. Afatinib dimaleate is an irreversible EGFR family inhibitor with IC50s of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFRwt, EGFRL858R, EGFRL858R/T790M and HER2, respectively[1][2].

HY-B0793S1

AZ-5104-d2
AZ-5104-d₂ is the deuterium labeled AZ-5104. AZ-5104 is an EGFR inhibitor with IC50s of 1 nM, 6 nM, 1 nM, 25 nM and 7 nM for EGFRL858R/T790M, EGFRL858R, EGFRL861Q, EGFR and ErbB4, respectively[1].

HY-B1486S

Oxprenolol-d7 hydrochloride
Oxprenolol-d₇ (hydrochloride) is the deuterium labeled Oxprenolol hydrochloride. Oxprenolol hydrochloride (Ba 39089) is an orally bioavailable β-adrenergic receptor (β-AR) antagonist with a Ki of 7.10 nM in a radioligand binding assay using rat heart muscle[1].

HY-17360S

Tiotropium-d3 bromide
Tiotropium-d₃ (bromide) is the deuterium labeled Tiotropium (Bromide). Tiotropium Bromide (BA679 BR) is a muscarinic acetylcholine receptor (mAChR) antagonist that blocks the binding of the acetylcholine ligand and subsequent opening of the ligand-gated ion channel.

HY-17360S1

Tiotropium-d6 bromide
Tiotropium-d₆ (bromide) is deuterium labeled Tiotropium (Bromide). Tiotropium Bromide (BA679 BR) is a muscarinic acetylcholine receptor (mAChR) antagonist that blocks the binding of the acetylcholine ligand and subsequent opening of the ligand-gated ion channel.

HY-W013780S

Fmoc-Pro-OH-1-13C
Fmoc-Pro-OH-1- ¹³C is a ¹³C-labeled Sulfabenzamide. Sulfabenzamide (N-Sulfanilylbenzamide) is an antimicrobial agent and usually consumed in combination with Sulfathiazole and Sulfacetamide. Sulfabenzamide is effective against Gram-positive and negative ba

HY-B2006S

Fenvalerate-d5
Fenvalerate-d₅ is the deuterium labeled Fenvalerate. Fenvalerate is a potent protein phosphatase 2B (calcineurin) inhibitor with an IC50 of 2-4 nM for PP2B-Aα. Fenvalerate is a pyrethroid ester insecticide and acaricide[1].

HY-B1486AS

Oxprenolol-d7
Oxprenolol-d₇ is the deuterium labeled Oxprenolol. Oxprenolol (Ba 39089 free base) is an orally bioavailable β-adrenergic receptor (β-AR) antagonist with a Ki of 7.10 nM in a radioligand binding assay using rat heart muscle[1].

HY-41700S1

D-Alanine-d4

D-Alanine-d₄ is the deuterium labeled D-Alanine. D-Alanine is a weak GlyR (inhibitory glycine receptor) and PMBA agonist, with an EC50 of 9 mM for GlyR.
HY-41700S

D-Alanine-d3

D-Alanine-d₃ is the deuterium labeled D-Alanine. D-Alanine is a weak GlyR (inhibitory glycine receptor) and PMBA agonist, with an EC50 of 9 mM for GlyR.
HY-41700S2

D-Alanine-d1

D-Alanine-d is the deuterium labeled D-Alanine. D-Alanine is a weak GlyR (inhibitory glycine receptor) and PMBA agonist, with an EC50 of 9 mM for GlyR[1].
HY-41700S3

D-Alanine-d7

D-Alanine-d₇ is the deuterium labeled D-Alanine. D-Alanine is a weak GlyR (inhibitory glycine receptor) and PMBA agonist, with an EC50 of 9 mM for GlyR.

Cat. No.	Product Name		Classification

HY-15164

Icotinib Hydrochloride 5+ Cited Publications BPI-2009H		Alkynes
Icotinib Hydrochloride (BPI-2009) is a potent and specific EGFR inhibitor with an IC₅₀ of 5 nM; also inhibits mutant EGFR ^L858R, EGFR ^L858R/T790M, EGFR ^T790M and EGFR ^L861Q. Icotinib (Hydrochloride) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-15164A

Icotinib 5+ Cited Publications BPI-2009		Alkynes
Icotinib (BPI-2009) is a potent and specific EGFR inhibitor with an IC₅₀ of 5 nM; also inhibits mutant EGFR ^L858R, EGFR ^L858R/T790M, EGFR ^T790M and EGFR ^L861Q. Icotinib is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-104066

Theliatinib Xiliertinib; HMPL-309		Alkynes
Theliatinib (Xiliertinib) is a potent, ATP-competitive, orally active and highly selective EGFR inhibitor with a K_i of 0.05 nM and an IC₅₀ of 3 nM. Theliatinib has an IC₅₀ of 22 nM for *EGFR T790M/L858R* mutant. Theliatinib shows >50-fold selectivity for EGFR** than other kinases . Theliatinib is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-104066A

Theliatinib tartrate Xiliertinib tartrate; HMPL-309 tartrate		Alkynes
Theliatinib (Xiliertinib) tartrate is a potent, ATP-competitive, orally active and highly selective EGFR inhibitor with a K_i of 0.05 nM and an IC₅₀ of 3 nM. Theliatinib has an IC₅₀ of 22 nM for *EGFR T790M/L858R* mutant. Theliatinib shows >50-fold selectivity for EGFR** than other kinases . Theliatinib (tartrate) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-147858

PROTAC EGFR degrader 7		Alkynes
PROTAC EGFR degrader 7 (compound 13b) is a potent and selective CRBN-recruiting PROTAC EGFR ^L858R/T790M degrader, with a DC₅₀ of 13.2 nM. PROTAC EGFR degrader 7 inhibits NCI–H1975 cells proliferation, with an IC₅₀ of 46.82 nM. PROTAC EGFR degrader 7 significantly induces apoptosis and G2/M phase arrest in NCI–H1975 cell. PROTAC EGFR degrader 7 shows antitumor activity, and can be used for non-small cell lung cancer (NSCLC) research . PROTAC EGFR degrader 7 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks